Benzinga | Sep 30, 2020 08:03AM EDT

I-Mab Receives China CDE Approval To Initiate Phase 3 Clinical Trial Of Eftansomatropin In Pediatric Patients With Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Sept. 30, 2020 /PRNewswire/ --I-Mab (the "Company") (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China Centerfor Drug Evaluation (CDE) has approved the pivotal trial application for eftansomatropin (also known as TJ101) as a weekly treatment for growth hormone deficiency in pediatric patients (PGHD).